Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Receives $34.33 Consensus Price Target from Analysts

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) has earned an average rating of “Moderate Buy” from the five brokerages that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $34.3333.

Several research analysts have issued reports on the company. Wall Street Zen upgraded Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, November 2nd. Guggenheim reaffirmed a “buy” rating on shares of Unicycive Therapeutics in a research note on Tuesday, December 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Monday, December 29th. HC Wainwright reissued a “buy” rating and set a $22.00 price target (up previously from $9.00) on shares of Unicycive Therapeutics in a research report on Wednesday, October 29th. Finally, Westpark Capital began coverage on shares of Unicycive Therapeutics in a research report on Thursday. They set a “buy” rating on the stock.

Institutional Investors Weigh In On Unicycive Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. raised its position in shares of Unicycive Therapeutics by 11,698.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 21,709 shares of the company’s stock valued at $104,000 after acquiring an additional 21,525 shares in the last quarter. Lazard Asset Management LLC acquired a new stake in shares of Unicycive Therapeutics during the second quarter worth $55,000. Vanguard Group Inc. lifted its position in shares of Unicycive Therapeutics by 8.7% in the 3rd quarter. Vanguard Group Inc. now owns 658,878 shares of the company’s stock worth $2,873,000 after buying an additional 52,925 shares during the last quarter. Squarepoint Ops LLC acquired a new position in shares of Unicycive Therapeutics in the 3rd quarter valued at about $512,000. Finally, Citadel Advisors LLC bought a new stake in shares of Unicycive Therapeutics during the 3rd quarter valued at about $182,000. Institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics Trading Down 3.5%

Unicycive Therapeutics stock opened at $6.28 on Thursday. Unicycive Therapeutics has a twelve month low of $3.71 and a twelve month high of $11.00. The stock has a 50 day moving average of $6.20 and a two-hundred day moving average of $5.28. The stock has a market capitalization of $134.96 million, a price-to-earnings ratio of -1.59 and a beta of 1.85.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.